Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer
ABSTRACT Purpose The prognosis of microinvasive breast cancer (MIBC) is controversial, with a high reported rate of local recurrence (LR). This study aimed to evaluate the characteristics, treatments, and prognosis of patients with MIBC compared to those with carcinoma in situ (CIS) or early invasiv...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70297 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329012709523456 |
|---|---|
| author | Ran Song Dong‐Eun Lee So‐Youn Jung Seeyoun Lee Han‐Sung Kang Jai Hong Han Jaeyeon Woo Eun‐Gyeong Lee |
| author_facet | Ran Song Dong‐Eun Lee So‐Youn Jung Seeyoun Lee Han‐Sung Kang Jai Hong Han Jaeyeon Woo Eun‐Gyeong Lee |
| author_sort | Ran Song |
| collection | DOAJ |
| description | ABSTRACT Purpose The prognosis of microinvasive breast cancer (MIBC) is controversial, with a high reported rate of local recurrence (LR). This study aimed to evaluate the characteristics, treatments, and prognosis of patients with MIBC compared to those with carcinoma in situ (CIS) or early invasive cancer. Methods Patients who diagnosed with CIS or stage I breast cancer were retrospectively enrolled. Using the Kaplan–Meier method, local recurrence‐free survival (LRFS), systemic recurrence‐free survival (SRFS), and cancer‐specific survival (CSS) were compared according to T stage. The prognostic factors associated with LRFS were identified using the Cox proportional hazards model. Results According to T stage, 517 (21.6%), 200 (8.4%), 207 (8.7%), 363 (15.2%), and 1101 (46.1%) patients had Tis, T1mi, T1a, T1b, and T1c tumors, respectively. The proportion of human epidermal growth factor receptor 2‐positive tumors was significantly higher in patients with MIBC (p < 0.0001). The administered adjuvant treatments also showed differences according to T stage (p < 0.0001). During the 73‐month median follow‐up period, patients with MIBC showed significantly worse LRFS than those with T1a or T1c tumors (p = 0.002). There was no significant difference in SRFS and CSS. In the Cox regression analysis, tumor multiplicity (p = 0.017), Ki‐67 (p = 0.025), cancer subtype (p = 0.034), adjuvant endocrine therapy (p = 0.003), and adjuvant radiation therapy (p < 0.0001) were significant prognostic factors associated with LRFS. Conclusion The risk of LR was higher in patients with MIBC than in those with small invasive breast cancer. Therefore, if indicated, adjuvant endocrine and radiation therapies should be administered to prevent undertreatment in patients with MIBC. |
| format | Article |
| id | doaj-art-31b61140caeb4e3e82554d7b6b29a80f |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-31b61140caeb4e3e82554d7b6b29a80f2025-08-20T03:47:24ZengWileyCancer Medicine2045-76342024-10-011319n/an/a10.1002/cam4.70297Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast CancerRan Song0Dong‐Eun Lee1So‐Youn Jung2Seeyoun Lee3Han‐Sung Kang4Jai Hong Han5Jaeyeon Woo6Eun‐Gyeong Lee7Department of Surgery Konyang University Hospital, Konyang University College of Medicine Daejeon Republic of KoreaBiostatistics Collaboration Team, Research Core Center Research Institute of National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaDepartment of Surgery, Center of Breast Cancer National Cancer Center Goyang Republic of KoreaABSTRACT Purpose The prognosis of microinvasive breast cancer (MIBC) is controversial, with a high reported rate of local recurrence (LR). This study aimed to evaluate the characteristics, treatments, and prognosis of patients with MIBC compared to those with carcinoma in situ (CIS) or early invasive cancer. Methods Patients who diagnosed with CIS or stage I breast cancer were retrospectively enrolled. Using the Kaplan–Meier method, local recurrence‐free survival (LRFS), systemic recurrence‐free survival (SRFS), and cancer‐specific survival (CSS) were compared according to T stage. The prognostic factors associated with LRFS were identified using the Cox proportional hazards model. Results According to T stage, 517 (21.6%), 200 (8.4%), 207 (8.7%), 363 (15.2%), and 1101 (46.1%) patients had Tis, T1mi, T1a, T1b, and T1c tumors, respectively. The proportion of human epidermal growth factor receptor 2‐positive tumors was significantly higher in patients with MIBC (p < 0.0001). The administered adjuvant treatments also showed differences according to T stage (p < 0.0001). During the 73‐month median follow‐up period, patients with MIBC showed significantly worse LRFS than those with T1a or T1c tumors (p = 0.002). There was no significant difference in SRFS and CSS. In the Cox regression analysis, tumor multiplicity (p = 0.017), Ki‐67 (p = 0.025), cancer subtype (p = 0.034), adjuvant endocrine therapy (p = 0.003), and adjuvant radiation therapy (p < 0.0001) were significant prognostic factors associated with LRFS. Conclusion The risk of LR was higher in patients with MIBC than in those with small invasive breast cancer. Therefore, if indicated, adjuvant endocrine and radiation therapies should be administered to prevent undertreatment in patients with MIBC.https://doi.org/10.1002/cam4.70297breast cancercarcinoma in situinvasive carcinomamicroinvasionprognosisrecurrence |
| spellingShingle | Ran Song Dong‐Eun Lee So‐Youn Jung Seeyoun Lee Han‐Sung Kang Jai Hong Han Jaeyeon Woo Eun‐Gyeong Lee Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer Cancer Medicine breast cancer carcinoma in situ invasive carcinoma microinvasion prognosis recurrence |
| title | Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer |
| title_full | Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer |
| title_fullStr | Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer |
| title_full_unstemmed | Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer |
| title_short | Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis‐T1 Breast Cancer |
| title_sort | unveiling the clinical path of microinvasive breast cancer a comparative study with tis t1 breast cancer |
| topic | breast cancer carcinoma in situ invasive carcinoma microinvasion prognosis recurrence |
| url | https://doi.org/10.1002/cam4.70297 |
| work_keys_str_mv | AT ransong unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT dongeunlee unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT soyounjung unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT seeyounlee unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT hansungkang unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT jaihonghan unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT jaeyeonwoo unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer AT eungyeonglee unveilingtheclinicalpathofmicroinvasivebreastcanceracomparativestudywithtist1breastcancer |